Navigation Links
FASgen Announces Significant Milestone in Its Cancer Drug Development Program
Date:10/1/2007

BALTIMORE, Oct. 1 /PRNewswire/ -- FASgen's fatty acid synthase inhibitor (FASi) compounds, led by FAS031, have demonstrated efficacy against every solid tumor xenograft cell line tested, in both orthotopic and flank models: 4 lung tumor cell lines (H460; A549; H1975; LX7); two ovarian; breast; and, colon. In many cases the tumors were eradicated entirely. The compounds have been shown in extensive preclinical studies to be remarkably safe and orally available. One compound was safely given to mice twice a day orally for 6 months with no observed adverse side effects except the elimination of the tumors. Other compounds were given to mice in a two year experiment and prevented the onset of tumors in nearly one-third of the mice. That experiment was repeated with a different compound and produced the same result. Several of these results have been recently published and others will shortly be published in leading oncology journals.

FASi is a new mechanism of action for the treatment of cancer. The fatty acid biosynthesis pathway is critical to all living organisms to produce fat and regulate the body's energy. In cancer cells, FASgen researchers over the last 15 years have discovered that the mechanism acts differently. As cancer cells do not produce fat, the fatty acid biosynthesis pathway in the transformed cell acts to regulate the energy source that keeps the cell alive. One critical enzyme in that pathway is FAS. The Company's researchers have discovered that inhibition of FAS kills the cancer cell, a result that has been recently replicated in a number of labs and become the subject of a series of new publications. FASgen has developed a library of FASi compounds and has an extensive body of intellectual property surrounding both the mechanism of action and uses for the compounds, and of course the composition of individual compounds. "This discovery holds out the prospect for a new method of treatment for cancer that is remarkably safe and may dimi
'/>"/>

SOURCE FASgen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... Ortho-McNeil Neurologics, a,division of Ortho-McN...,that the U.S. Food and Drug Administration (FDA) ...topiramate), based on studies submitted in,respons...he use of TOPAMAX,in pediatric patients aged 1 to ...on to granting pediatric exclusivity, the FDA is c...
(Date:7/24/2008)...re/ -- There are a record 301,new medicines being ...,report released here today during a briefing that...lnesses have on patients, their families,and soci...million American,adults. The briefing, led by the ...ca (PhRMA), featured Emmy Award-winning actor Joey...
(Date:7/24/2008)...e body temperature, for home,and clinical use, WE...z-Med, Inc.,(subsidiary of American Scientific Res...ributor of the Thermofocus(R) 5-in-1 non-contact,t...a clinical study,conducted by the Second Children,...ly, which proves that the Thermofocus(R) measures ...
(Date:7/23/2008)...apy to Treat the Disease -, WAYNE, N.J. and EMERY...ayer HealthCare Pharmaceuticals and Onyx Pharmaceu...he New England Journal of Medicine published,resul...) (sorafenib),tablets decreased the absolute risk ...le hepatocellular carcinoma (HCC), or liver cancer...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Some Epilepsy Patients Are Good Candidates for Surgery 183 1Some Epilepsy Patients Are Good Candidates for Surgery 183 2GERD Not Limited to Grownups 181 1GERD Not Limited to Grownups 181 2GERD Not Limited to Grownups 181 3Anadys Pharmaceuticals Appoints Steve Worland Ph D as President and Chief Executive Officer 181 1Anadys Pharmaceuticals Appoints Steve Worland Ph D as President and Chief Executive Officer 181 2Anadys Pharmaceuticals Appoints Steve Worland Ph D as President and Chief Executive Officer 181 3Social parasites of the smaller kind 150 1Social parasites of the smaller kind 150 2
...lo., June 11, 2007 /PRNewswire/ -- Accera, Inc.,to...n of its Phase,IIb clinical trial of AC-1202 (Keta...s Association,s International Conference on,Preven...th the,findings of earlier clinical and preclinica...nificantly improve the memory and,cognition of sub...
....--(BUSINESS WIRE)--Jun 12, 2007 - Critical,Therap...blication,of data from a pivotal Phase III clinica...e tablets in the June 2007 issue of the,Journal of...d Drug,Administration (FDA) on May 30, 2007. Criti...artner Dey, L.P. (DEY), expects to,begin marketing...
Other Medicine Technology:Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
(Date:7/25/2008)... HOUSTON, July 25 /PRNewswire/ -- The Elekta Famil...cancer treatment solutions at the 2008,American As...meeting,demonstrating how the joint forces of Ele...iation therapy planning and delivery solutions tha...ter experience for,patients, as well as enhance cl...
(Date:7/25/2008)...urday can be toughest for those trying to drop pou...althDay News) -- Anyone who has avoided Monday mor...nds are not a dieter,s friend. , Now, researche...s about weekends being their undoing: Most people ...ng to lose weight. , "Weekend indulgences can w...
(Date:7/25/2008)... The Drug Information Associ...FDA) will host the Critical Path Initiative (CPI) ...r 15 -16; Bethesda, MD) and the Critical Path Tran.... , Horsham, PA (PRWEB) J... Information Association (DIA)] and the Food and D...
(Date:7/24/2008)... Hoag to lease hospital faci... Newport Beach, CA (Vocus) July 24, 2008 -- Hoa...reement with HCP, Inc. (NYSE: HCP), a Real Estate ...to lease its 175-bed hospital facility on Sand Can..., , , ,The facility is currently operated by Tene...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2
...euroscientists at Harvard Medical School and its a...o stress hormone in mice directly results in the a...issue of Behavioral Neuroscience, which is publish...iation, has this article. This would be helpful i...
...hwarz Pharma AG under which it would be acquiring ...drug that can be a treatment option for an overact...ing condition that affects up to 100 million peopl...ice chairman of Pfizer Inc and president, Pfizer H...
...ed deeply about fat cells, called adipocytes which...arch has now revealed that these Fat cells around ...heart disease. University of Iowa researchers have...cals that can cause inflammation. Fat cells, once...
...government a confirmed case of mad-cow disease in ...case was of a 6-year-old dairy cow which was ident...urveillance program for mad-cow disease. In a writ...es not affect the safety of Canadian beef. Tissues...
Other Medicine News:Health News:Link Between Stress Hormone And Depression Revealed 2Health News:Fat cells lethally connected to heart disease 2
... IOL power calculation software. All A-scans and A...e module with SRK II, SRKT, Holladay Dioptimum and...H 5100e are equipped with corneal compression dete...eadings. The only A-Scan in the world with corneal...
The AccuSonic A-scan makes it easy to obtain extreme accuracy and improved patient outcomes. Obtain accurate measurements with industry leading signal acquisition and processing.
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w
The UD-6000 combines all the functions of modern ultrasound diagnostics used in ophthalmology: The latest generation high resolution A/B-sector scanner, a diagnostic A-mode scanner with an optional p
Medicine Products: